Literature DB >> 25122776

Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.

Julie Sheldon1, Nathan M Beach1, Elena Moreno1, Isabel Gallego2, David Piñeiro1, Encarnación Martínez-Salas1, Josep Gregori3, Josep Quer4, Juan Ignacio Esteban4, Charles M Rice5, Esteban Domingo6, Celia Perales6.   

Abstract

Passage of hepatitis C virus (HCV) in human hepatoma cells resulted in populations that displayed partial resistance to alpha interferon (IFN-α), telaprevir, daclatasvir, cyclosporine, and ribavirin, despite no prior exposure to these drugs. Mutant spectrum analyses and kinetics of virus production in the absence and presence of drugs indicate that resistance is not due to the presence of drug resistance mutations in the mutant spectrum of the initial or passaged populations but to increased replicative fitness acquired during passage. Fitness increases did not alter host factors that lead to shutoff of general host cell protein synthesis and preferential translation of HCV RNA. The results imply that viral replicative fitness is a mechanism of multidrug resistance in HCV. Importance: Viral drug resistance is usually attributed to the presence of amino acid substitutions in the protein targeted by the drug. In the present study with HCV, we show that high viral replicative fitness can confer a general drug resistance phenotype to the virus. The results exclude the possibility that genomes with drug resistance mutations are responsible for the observed phenotype. The fact that replicative fitness can be a determinant of multidrug resistance may explain why the virus is less sensitive to drug treatments in prolonged chronic HCV infections that favor increases in replicative fitness.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25122776      PMCID: PMC4178724          DOI: 10.1128/JVI.01860-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  97 in total

1.  Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites.

Authors:  Lihui Deng; Hong Tang
Journal:  Hepatol Res       Date:  2011-09-15       Impact factor: 4.288

2.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

3.  Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection.

Authors:  Natalia Tapia; Guerau Fernàndez; Mariona Parera; Gemma Gómez-Mariano; Bonaventura Clotet; Miguel Quiñones-Mateu; Esteban Domingo; Miguel Angel Martínez
Journal:  Virology       Date:  2005-07-20       Impact factor: 3.616

4.  Transient expression of cellular polypyrimidine-tract binding protein stimulates cap-independent translation directed by both picornaviral and flaviviral internal ribosome entry sites In vivo.

Authors:  R Gosert; K H Chang; R Rijnbrand; M Yi; D V Sangar; S M Lemon
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

5.  The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors:  George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Foot-and-mouth disease virus infection induces proteolytic cleavage of PTB, eIF3a,b, and PABP RNA-binding proteins.

Authors:  Miguel Rodríguez Pulido; Paula Serrano; Margarita Sáiz; Encarnación Martínez-Salas
Journal:  Virology       Date:  2007-04-18       Impact factor: 3.616

7.  Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.

Authors:  John M Robida; Heather B Nelson; Zhe Liu; Hengli Tang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

Review 8.  Perspectives and challenges of interferon-free therapy for chronic hepatitis C.

Authors:  Christian M Lange; Stefan Zeuzem
Journal:  J Hepatol       Date:  2012-10-24       Impact factor: 25.083

9.  Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

Authors:  Chunfu Wang; Jin-Hua Sun; Donald R O'Boyle; Peter Nower; Lourdes Valera; Susan Roberts; Robert A Fridell; Min Gao
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  32 in total

1.  Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.

Authors:  Mitsuaki Sato; Shinya Maekawa; Nobutoshi Komatsu; Akihisa Tatsumi; Mika Miura; Masaru Muraoka; Yuichiro Suzuki; Fumitake Amemiya; Shinichi Takano; Mitsuharu Fukasawa; Yasuhiro Nakayama; Tatsuya Yamaguchi; Tomoyoshi Uetake; Taisuke Inoue; Tadashi Sato; Minoru Sakamoto; Atsuya Yamashita; Kohji Moriishi; Nobuyuki Enomoto
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

2.  Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.

Authors:  B Dominguez-Molina; K Machmach; C Perales; L Tarancon-Diez; I Gallego; J L Sheldon; M Leal; E Domingo; E Ruiz-Mateos
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

3.  Broad and Dynamic Diversification of Infectious Hepatitis C Virus in a Cell Culture Environment.

Authors:  Isabel Gallego; María Eugenia Soria; Carlos García-Crespo; Qian Chen; Patricia Martínez-Barragán; Soumaya Khalfaoui; Brenda Martínez-González; Irene Sanchez-Martin; Inés Palacios-Blanco; Ana Isabel de Ávila; Damir García-Cehic; Juan Ignacio Esteban; Jordi Gómez; Carlos Briones; Josep Gregori; Josep Quer; Celia Perales; Esteban Domingo
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

4.  HIV-1 Adapts To Replicate in Cells Expressing Common Marmoset APOBEC3G and BST2.

Authors:  Alberto Fernández-Oliva; Andrés Finzi; Hillel Haim; Luis Menéndez-Arias; Joseph Sodroski; Beatriz Pacheco
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

Review 5.  Viral quasispecies.

Authors:  Raul Andino; Esteban Domingo
Journal:  Virology       Date:  2015-03-29       Impact factor: 3.616

6.  Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment.

Authors:  Elena Moreno; Isabel Gallego; Josep Gregori; Adriana Lucía-Sanz; María Eugenia Soria; Victoria Castro; Nathan M Beach; Susanna Manrubia; Josep Quer; Juan Ignacio Esteban; Charles M Rice; Jordi Gómez; Pablo Gastaminza; Esteban Domingo; Celia Perales
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 7.  Quasispecies and virus.

Authors:  Esteban Domingo; Celia Perales
Journal:  Eur Biophys J       Date:  2018-02-03       Impact factor: 1.733

8.  Synergistic lethal mutagenesis of hepatitis C virus.

Authors:  Isabel Gallego; María Eugenia Soria; Josep Gregori; Ana I de Ávila; Carlos García-Crespo; Elena Moreno; Ignacio Gadea; Jaime Esteban; Ricardo Fernández-Roblas; Juan Ignacio Esteban; Jordi Gómez; Josep Quer; Esteban Domingo; Celia Perales
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

9.  Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants.

Authors:  Nadezhda T Doncheva; Francisco S Domingues; David R McGivern; Tetsuro Shimakami; Stefan Zeuzem; Thomas Lengauer; Christian M Lange; Mario Albrecht; Christoph Welsch
Journal:  J Mol Biol       Date:  2019-04-30       Impact factor: 5.469

10.  Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.

Authors:  Georg Dultz; Tetsuro Shimakami; Markus Schneider; Kazuhisa Murai; Daisuke Yamane; Antoine Marion; Tobias M Zeitler; Claudia Stross; Christian Grimm; Rebecca M Richter; Katrin Bäumer; MinKyung Yi; Ricardo M Biondi; Stefan Zeuzem; Robert Tampé; Iris Antes; Christian M Lange; Christoph Welsch
Journal:  J Biol Chem       Date:  2020-08-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.